Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Brainsway ( (BWAY) ).
On October 27, 2025, BrainsWay Ltd. announced two additional minority stake investments in U.S. mental health providers, including an equity financing agreement with Tangient ATX Inc., which manages the Heading Health clinic network in Texas. These strategic investments, which bring the total to four in 2025, aim to enhance shareholder value by expanding patient access to innovative mental health treatments and supporting the growth of BrainsWay’s commercial partners.
The most recent analyst rating on (BWAY) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The technical analysis supports a bullish outlook, although the high P/E ratio suggests valuation concerns. The absence of corporate events and dividend yield slightly tempers the overall score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is committed to advancing neuroscience and increasing global awareness of Deep TMS.
Average Trading Volume: 68,572
Technical Sentiment Signal: Buy
Current Market Cap: $315.5M
Find detailed analytics on BWAY stock on TipRanks’ Stock Analysis page.